<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1705">
  <stage>Registered</stage>
  <submitdate>1/10/2007</submitdate>
  <approvaldate>1/10/2007</approvaldate>
  <nctid>NCT00538356</nctid>
  <trial_identification>
    <studytitle>Influence of Home Monitoring on the Clinical Status of Heart Failure Patients With an Impaired Left Ventricular Function</studytitle>
    <scientifictitle>IN-TIME: Influence of Home Monitoring on the Clinical Status of Heart Failure Patients</scientifictitle>
    <utrn />
    <trialacronym>IN-TIME</trialacronym>
    <secondaryid>There is no secondary ID</secondaryid>
    <secondaryid>HS042</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ventricular Fibrillation</healthcondition>
    <healthcondition>Ventricular Tachycardia</healthcondition>
    <healthcondition>Congestive Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - ICD or CRT-D with Home Monitoring feature deactivated
Treatment: devices - ICD or CRT-D with Home Monitoring feature activated

Experimental: Home Monitoring - ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events

Active Comparator: Control - ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic


Treatment: devices: ICD or CRT-D with Home Monitoring feature deactivated
Standard care

Treatment: devices: ICD or CRT-D with Home Monitoring feature activated
Standard care + patient management by Home Monitoring

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite Score of death, hospitalization for heart failure, NYHA class and global assessment (Packer Score)</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rehospitalizations due to worsening heart failure; Correlation of Home Monitoring values with the clinical status; Incidence and reasons for Home Monitoring based interventions; Home Monitoring workflow analysis</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Indication for single chamber ICD, dual chamber ICD or CRT-D

          -  Chronic heart failure (= 3 months)

          -  NYHA Class II or III for 1 month prior to screening

          -  LVEF = 35% within 3 months prior to screening

          -  Indication for therapy with diuretics

          -  Patient informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Uncontrolled hypertension

          -  NYHA class I or IV

          -  Permanent atrial fibrillation

          -  Life expectancy &lt; 1 year

          -  Restrictive, infiltrative or hypertrophic cardiomyopathy, constrictive pericarditis,
             acute myocarditis

          -  Severe mitral regurgitation

          -  Symptomatic aortic stenosis

          -  Tricuspid valve replacement

          -  Known drug or alcohol abuse

          -  Expected non-compliance

          -  Pregnancy

          -  Participation in another telemonitoring concept

          -  Participation in another study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>720</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sydney Adventist Hospital - Wahroonga</hospital>
    <postcode>2076 - Wahroonga</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aalborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hellerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Odense</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Århus N</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Berka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Neustadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Segeberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bielefeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Detmold</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gießen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg/Saar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lübeck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lünen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich - Schwabing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordhausen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Paderborn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Pirna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach-Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biotronik SE &amp; Co. KG</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Re-hospitalizations or deaths by worsening heart failure are often preceded by distinct
      trends of clinical parameters such as atrial or ventricular arrhythmia, activity, heart rate
      variability, or ventricular ectopy. The Home Monitoring capability offered by BIOTRONIK
      active implants has the potential to detect some of these trends early and thus to offer the
      possibility to intervene in time for prevention of fatal worsening of heart failure.

      To investigate the predictive value of Home Monitoring parameters, patients with symptomatic
      heart failure and reduced ejection fraction receiving an implantable
      cardioverter-defibrillator (ICD) or an ICD in combination with cardiac resynchronization
      therapy (CRT-D) will be randomized between prospective patient management by Home Monitoring
      analysis or standard care. The influence of Home Monitoring on the clinical status of heart
      failure patients will be assessed.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00538356</trialwebsite>
    <publication>Arya A, Block M, Kautzner J, Lewalter T, Mörtel H, Sack S, Schumacher B, Søgaard P, Taborsky M, Husser D, Hindricks G; IN-TIME investigators. Influence of Home Monitoring on the clinical status of heart failure patients: Design and rationale of the IN-TIME study. Eur J Heart Fail. 2008 Nov;10(11):1143-8. doi: 10.1016/j.ejheart.2008.08.004. Epub 2008 Sep 19.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gerhard Hindricks, Prof. Dr.</name>
      <address>Herzzentrum Leipzig, Germany</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>